R&D How Europe can harness the full potential of biosimilars Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.
R&D No longer the little fish: How Europe is holding its own thr... It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.
Market Access Neurotech patents in Europe: Methods, medical devices, and t... The field of neurotechnology is rapidly evolving, bringing together advances in neuroscience, engineering, materials science, and computing.
Market Access Early strategic evidence planning is a key success factor in... As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
